User:Luke Edward Severinac/Sandbox 1

From Proteopedia

< User:Luke Edward Severinac(Difference between revisions)
Jump to: navigation, search
Current revision (21:52, 24 April 2017) (edit) (undo)
 
(177 intermediate revisions not shown.)
Line 1: Line 1:
== '''Caspase-6 in ''Homo sapiens''' ==
== '''Caspase-6 in ''Homo sapiens''' ==
-
<StructureSection load='4FXO' size='340' side='right' caption='Caspase-6' scene=''>
+
<StructureSection load='4IYR' size='340' side=http://proteopedia.org/wiki/index.php?title=User:Luke_Edward_Severinac/Sandbox_1&action=edit'right' caption='Caspase-6' scene=''>
-
Found at high concentrations in the brain and bordering tissues, Caspase-6 has been implicated in several neurological diseases including Alzheimer's and dementia. It's primarily involved in apoptosis through a largely ambiguous mechanism. It is classified as an [https://en.wikipedia.org/wiki/Endopeptidase]endopeptidase as it cleaves an internal peptide bond of its substrate. It has relatively low specificity in the binding site which allows for a variety of substrates, including other caspase enzymes to bind. Furthermore, it is a part of the cysteine aspartate family, which have these critical amino acid residues in the active site of the enzyme. Caspase-6 has both an inactive zinc-bound conformation and an active ligand-bound conformation, which are largely regulated by variations in zinc concentration.
+
Caspase-6 is an [https://en.wikipedia.org/wiki/Endopeptidase endopeptidase] involved in apoptosis. In terms of its catalytic function, it is a part of the [https://en.wikipedia.org/wiki/Caspase cysteine-aspartate family]. Before Caspase-6 becomes functional, the enzyme exists as a <scene name='75/752344/Caspase-6_zymogen/1'>procaspase</scene>, also known as a [https://en.wikipedia.org/wiki/Zymogen zymogen]. This zymogen exists as a <scene name='75/752344/Caspase-6_zymogen/1'>homodimer</scene>, whose <scene name='75/752344/Caspase-6_zymogen_realller/1'>monomeric units</scene> are then cleaved at <scene name='75/752344/Caspase-6_cleavage_sites_real/1'>specific sites</scene> to assume its active conformation. Zymogen activation through cleavage is largely conserved across the caspase family. However, Caspase-6 is unique in that it becomes active through self-cleavage in addition to cleavage by a separate enzymes<ref name="zincmedallinhib">PMID: 22891250 </ref>. Each monomeric unit of zymogen contains a <scene name='75/752344/Caspase-6_small_subunit_mnmr/1'>small subunit</scene> consisting of two helices, a <scene name='75/752344/Caspase-6_large_real_yeahboi/1'>large subunit</scene> consisting of three helices, a <scene name='75/752344/Caspase-6_prodomain/1'>prodomain</scene>, and a <scene name='75/752344/Caspase-6_zymogen_b-sheet/1'>beta sheet core</scene>. After cleavage at all sites, the processed post-zymogen monomers remain closely associated together through intermolecular forces as a dimer.
-
[[Image:Caspase-6 protein.jpg|100 px|left|thumb|Figure Legend]]
+
=='''Zymogen'''==
-
[[Image:4FXO.PNG|100 px|left|thumb|This is the figure legend of the thumbnail]]
+
In addition to a self-cleavage mechanism, Caspase-6 <scene name='75/752344/Caspase-6_zymogen_yeahboi/1'>zymogen</scene> can be activated through cleavage by Caspase-3, as well as other enzymes. This activation by cleavage is highly conserved across the caspase family, but activation through self-cleavage is uniquely recognized as the primary mechanism for Caspase-6 activation. In this self-cleavage mechanism, cleavage must occur at <scene name='75/752344/Caspase-6_cleavage_sites_real/1'>three sites</scene> in order to remove the <scene name='75/752344/Caspase-6_prodomain/1'>pro-domain</scene> located at the N-terminus and the <scene name='75/752344/Caspase-6_intersubunit_linker/1'>intersubunit linker</scene> located within the protein. These cleavages are both sequence specific and ordered, starting with cleavage of the pro-domain at <scene name='75/752344/Caspase-6_prodomain_cleavage/1'>residue 30</scene>. Removal of the intersubunit linker then occurs through cleavage at two sites, <scene name='75/752344/Caspase-6_176-179_cleavageyis/1'>DVVD179 and TEVD193</scene><ref name="RegMechStructure">PMID: 24419379 </ref>. It has been proposed that this sequence of cleavage is due to the pro-domain being more readily available to enter the active site, whose presence inhibits Caspase-6's ability to cleave the intersubunit loop and self-activate; The prodomain acts as a “suicide protector”, preventing the TEVD193 cleavage site from the active site<ref name="ActRegofCas6inND">PMID: 25340928 </ref>. After both cleavages occur, <scene name='75/752344/Active_caspase_6_dimer/1'>active Caspase-6</scene> remains in solution as a dimer.
-
=='''Structure'''==
+
-
===Active Site===
+
-
In order to function as an endoprotease, Caspase-6 binds a <scene name='75/752344/Protein_ligand/1'>ligand</scene>, which can include neuronal proteins and tubulins, in its active site. This binding groove contains three critical amino acid residues necessary to perform cleavage of the peptide bonds. Together,<scene name='75/752344/His121/1'>His-121</scene>, <scene name='75/752344/Glu123/1'>Glu-123</scene>, and <scene name='75/752344/Cys163/1'>Cys-163</scene> form a <scene name='75/752344/Caspase-6_catalytic_triad_real/1'>catalytic triad</scene>[[Image:Mechanism caspase 6.PNG|100 px|left|thumb|Catalytic Triad Mechanism]]. In the theorized mechanism, His-121 provides hydrogen bonding to the carbonyl on the ligand. This stabilizs the tetrahedral intermediate formed when Cays-163 nucleuphilically attacks the protein. Glu-123 is used in the catalytic triad to deprotonate Cys-163, increasing the nucleophilicity of the residue.
+
 +
=='''Active State'''==
 +
[[Image:Binding grove active caspase 6.png|100 px|right|thumb|Substrate binding groove in Caspase-6. Blue - catalytic residues
 +
yellow - ligand
 +
red - generic surface]]
 +
In order to function as an endopeptidase, each <scene name='75/752344/Active_caspase_6_monomer/1'>monomer</scene> of active Caspase-6 utilizes a <scene name='75/752344/Catalytic_triad_real/1'>catalytic triad</scene> composed of <scene name='75/752344/Catalytic_his-121_monomer/1'>His-121</scene>, <scene name='75/752344/Catalytic_glu-123_monomer/1'>Glu-123</scene>, and <scene name='75/752344/Catalytic_cys-163_monomer/1'>Cys-163</scene> to cleave polypeptide ligands that can include neuronal proteins and [https://en.wikipedia.org/wiki/Tubulin tubulins]<ref name="ActiveStateCrys">PMID: 21917678 </ref>. In the theorized mechanism, atoms are shown in their resting ionic states; His-121 acts as an acid catalyst, Glu-123 acts as a base catalyst to deprotonate Cys-163, which then acts as covalent catalyst.
-
===Zinc Exosite===
+
[[Image:Cystine Aspartase.png|600 px|active site mechanism]]
 +
=='''Zinc Inhibition'''==
 +
Caspase-6 can also assume an inactive state, which exists as a <scene name='75/752344/Casp_6_inactive_dimer/1'>dimer</scene> in its biological unit. For each <scene name='75/752344/Casp_6_inactive_monomer/1'>monomer</scene>, Caspase-6 function is primarily inhibited by the binding of a <scene name='75/752344/Casp_6_inactive_monomer_zinc/1'>zinc</scene> ion, which binds to an <scene name='75/752344/Casp_6_alosteric_site/1'>allosteric site</scene> instead of the <scene name='75/752344/Casp_6_alostericactive_site/1'>active site</scene>. This allosteric site is located on the opposite side of the protein relative to the active site. The zinc ion is bound to <scene name='75/752344/Caspase6_alloster_resid/1'>three residues</scene>, Lys-36, Glu-244, and His-287. Once the ion is bound to the protein, it is then stabilized by a <scene name='75/752344/Caspase6_alloster_h20/1'>water molecule</scene> found in the cytoplasm. The binding of zinc at the exosite is suggested to cause a conformational change in the protein from an <scene name='75/752344/Catalytic_triad_real_monomer/1'>active state</scene> to an <scene name='75/752344/Casp_6_inactive_cat_triad/1'>inactive state</scene> that misaligns catalytic residues and inhibits activity of the enzyme. It has been proposed that helices of the active dimer must rotate or move in some other way to provide these ideal interactions with zinc. This subtle shift is most likely the cause for allosteric inhibition<ref name="zincmedallinhib">PMID: 22891250 </ref>. As the helices move to bind zinc, the amino acids of the active site become misaligned. The altered positions of the amino acids no longer provide ideal interactions for incoming substrates. After zinc binds, substrates may still enter the active site, but no catalytic activity will occur.
-
=='''Activation of Caspase-6'''==
+
[[Image:4FXO-FINAL.jpg|300px|Caspase-6 w/ Zinc Bound]] [[Image:3s70.jpg|300px|Caspase-6 w/o Zinc Bound]]
 +
The first image shows the catalytic triad of Caspase-6 with zinc bound, and the second image shows the catalytic triad of caspase-6 without zinc bound. The catalytic cysteine and glutamate residues flip positions and become misaligned resulting in a loss of enzymatic function.
-
===Structural Units involved in autoactivation===
+
=='''Phosphorylation'''==
-
Before Caspase-6 is a functional and active dimer, the enzyme exists as a procaspase. This precursor enzyme is modified by self-processing, a characteristic unique to Caspase-6. The unprocessed enzyme contains a small and large subunit, a pro domain, as well as a intersubunit linker. To become active, the intersubunit linker binds to the active site, where it is then cleaved. Other cleavages must occur as well for the enzyme to become active, specifically at TETD23 of the pro-domain, DVVD179, and TEVD193 amino acid sequences. Cleavage at these sites occurs in a specific sequence. To begin, the site within the pro-domain, TETD23, must be cleaved. This cleavage is then followed by either DVVD179 or TEVD193. It has been proposed that this sequence of cleavage is due to the structure of Caspase-6, which allows the pro-domain to be more readily available to enter the active site. To some extent, the pro-domain inhibits Caspase-6's ability to cleave the intersubunit loop and self-activate, but this also happens in a currently unknown mechanism. The pro-domain is released after the cleavage at TETD23, which then allows the two subunits to interact to form the active dimer.
+
The function of Caspase-6 can be inhibited by phosphorylation of Ser-257. The exact mechanism of this reaction remains unidentified at the time of publication, but proceeds when ARK5 kinase is present. This modification can occur before and after zymogen activation. The phosphoryl group inhibits Caspase-6 through steric interference. When Ser-257 is phosphorylated, the amino acid residue interacts with <scene name='75/752344/Caspase-6_his-208/1'>Pro-201</scene>, causing a shift in the helices of Caspase-6<ref name="ActRegofCas6inND">PMID: 25340928 </ref>. This is shown in the <scene name='75/752344/Caspase-6_s257d_mutantboi/1'>S257D Caspase-6 mutant</scene>, whose mutation mimics phosphorylation<ref name="Phosregcasp6subsbindgroove">PMID: 22483120 </ref>. The shift misaligns and disrupts residues found in the active site. This conformational difference prevents the intersubunit linker from entering during zymogen activation and the self-cleaved active dimer cannot be formed. Additionally, no new substrate is able to enter the active site.
-
Caspase-6 can also be activated by other caspases as an alternate to auto-activation.
+
=='''Medical Relevance'''==
-
 
+
-
It has been found that Caspase-6 can undergo activation without any other caspases, so there is a suggested self-cleavage mechanism for Caspase-6. The intramolecular cleavage of TEVD193 is essential for the initiation caspase-6 activation without Caspase-3 present. As mentioned above the pro-domain somehow inhibits the intramolecular cleavage of TEVD193, but currently the mechanism is not known. The TETD23 and TEVD193 cleavage sites are extremly similar to one another, but the TETD23 cleavage site is always cleaved before TEVD193. This indicates that the TETD23 cleavage site is more readily available for cleavage. The result of the TETD23 cleavage site priority is that the prodomain acts as a “suicide protector”, which protects the TEVD193 cleavage site from self-cleavage[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966951/]. This protection is useful when there are low levels of protein it also helps explain why the pro-domain inhibits self-activation.
+
-
 
+
-
=='''Inhibition'''==
+
-
===Zinc Inhibition===
+
-
Primary inhibition of Caspase-6 occurs when a zinc ion binds to the exosite containing Lys-36, Glu-244, and His-287 of the active dimer. In addition to these residues, the zinc interacts with one water molecule from the cytoplasm. It has been proposed that helices of the active dimer must rotate or move in some other way to provide these ideal interactions with zinc. This subtle shift is most likely the cause for allosteric inhibition. As the helices move to bind zinc, the amino acids of the active site become misaligned. The altered positions of the amino acids no longer provide ideal interactions for incoming substrates. After zinc binds, no new substrates enter the active site. Thus, Caspase-6 is effectively inhibited.
+
-
 
+
-
===Phosphorylation===
+
-
The function of Caspase-6 can be inhibited by phosphorylation of Ser-257. The exact mechanism of this reaction remains unidentified at the time of publication, but proceeds when ARK5 kinase is present. This modification can occur before and after zymogen activation or auto-processing. The phosphoryl group inhibits Caspase-6 through steric interference. When Ser-257 is phosphorylated, the amino acid residue interacts with Pro-201, causing a shift in the helices of Caspase-6. The shift misaligns and disrupts residues found in the active site. This conformational difference prevents the inter-subunit loop from entering during zymogen activation and the self-cleaved active dimer cannot be formed. Additionally, no new substrate is able to enter the active site.
+
-
 
+
-
 
+
-
=='''Function'''==
+
===Caspase-6 involvement in Alzheimer's Disease===
===Caspase-6 involvement in Alzheimer's Disease===
-
Caspase-6 activity is associated with the formation of lesions within the Alzheimer's Disease (AD) and they can become present very early on during the disease's progression. Proapoptotic protein p53 is present at increased levels within AD brains, which seems to directly increase the transcription of Caspase-6. Treatments of Alzheimer's include targeting active Caspase-6 proteins because staining has found active Caspase-6 within the hippocampus and cortex of the Brain within in mild, moderate, and severe cases of AD, which indicates that Caspase-6 plays a predominate role in the pathophysiology of Alzheimer's. There has been research conducted that shows activation of Caspase-6 in AD could cause disruption of the cytoskeleton network of neurons, which then causes handicapped synaptic plasticity.
+
Caspase-6 is known to be involved in many neurodegenerative diseases, one of which is Alzheimer's disease (AD). Caspase-6 activity is associated with the formation of lesions within the [http://www.alz.org/ Alzheimer's Disease].Lesions can be found in early stages of AD. A proapoptotic protein, p53, is present at increased levels within AD brains, which seems to directly increase the transcription of Caspase-6, which indirectly influences apoptosis of neurons. Future treatments of AD include selective inhibition of active Caspase-6 proteins; staining has found active Caspase-6 within the hippocampus and cortex of the brain within a varying severity of AD cases. This suggests that Caspase-6 plays a predominate role in the pathophysiology of AD. There has been research conducted that shows activation of Caspase-6 in AD could cause disruption of the cytoskeleton network of neurons and lead to neuronal apoptosis<ref name="ActRegofCas6inND">PMID: 25340928 </ref>.
-
 
+
-
 
+
-
 
+
-
 
+
-
==Luke's free space==
+
-
If <scene name='75/752344/Serine_257_highlighted/1'>Serine 257</scene> is <scene name='pdbligand=PO4:PHOSPHATE+ION'>Phospohrylated</scene> , the activity of this protein is inhibited.
+
-
 
+
-
 
+
-
If <scene name='pdbligand=ZN:ZINC+ION'>Zinc</scene> binds to the protein, the activity of the active site is inhibited.
+
-
 
+
-
Inactive state of caspase 6:
+
-
<scene name='75/752344/Uncleaved_caspase_6/1'>inactive caspase</scene>
+
-
 
+
-
== Relevance ==
+
-
 
+
-
</StructureSection>
+
-
== References ==
+
-
<references/>
+
-
Wang, Xiao-Jun, Qin Cao, Yan Zhang, and Xiao-Dong Su. "Activation and Regulation of Caspase-6 and Its Role in Neurodegenerative Diseases." Annual Review of Pharmacology and Toxicology 55.1 (2015): 553-72. Web.
+
-
 
+
-
Wang XJ, Cao Q, Liu X, Wang KT, Mi W, et al. 2010. Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation. EMBO Rep. 11: 841–47
+
-
(self cleavage article)
+
-
http://www.rcsb.org/pdb/explore/explore.do?structureId=2WDP (this is the non-self cleaved protien)
+
=='''References'''==
 +
{{reflist}}

Current revision

Caspase-6 in Homo sapiens

Caspase-6

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

Luke Edward Severinac

Personal tools